Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC using its next-generation solvent-free manufacturing process, a milestone that supports the product’s planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC, which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion.
The approval of the next-generation manufacturing process is significant because it addresses a key barrier to large-scale adoption: production capacity. By increasing yield fivefold, Regentis can meet anticipated demand more efficiently, reducing costs and improving supply chain reliability. This positions GelrinC as a competitive alternative to existing treatments for cartilage damage, which often involve more invasive procedures or limited efficacy. For patients, the 10-minute minimally invasive procedure offers a faster recovery and potentially better outcomes compared to traditional surgery.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The product aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is available. The company’s focus on expanding its European Centers of Excellence and surgeon training programs is expected to facilitate adoption among orthopedic surgeons.
The U.S. cartilage repair market is estimated at $3 billion, and Regentis plans to eventually seek FDA approval for GelrinC. However, the immediate focus is on European commercialization, leveraging the CE Mark and the new manufacturing approval. The company’s collaboration with Humanitas Research Hospital in Milan underscores its commitment to clinical validation and real-world evidence generation. For investors, the production yield improvement signals scalability and potential profitability, while for patients, it means broader access to an innovative therapy that could delay or avoid joint replacement surgery.
For more information, view the full press release at https://ibn.fm/Ths4h and the latest news at https://ibn.fm/RGNT.
